<DOC>
	<DOCNO>NCT00465322</DOCNO>
	<brief_summary>The purpose study determine influence fluvastatin atorvastatin platelet aggregation patient treat aspirin plavix coronary stenting . We hypothezied positive effect fluvastatin platelet aggregation level .</brief_summary>
	<brief_title>Effect Fluvastatin Top Clopidogrel Aspirin Patients After DES Implantation Platelet Aggregation</brief_title>
	<detailed_description>1 . Introduction Coronary stent implantation perform 80 % coronary intervention . The use stents significantly reduce re-stenosis rate revascularization comparison conventional balloon angioplasty . To prevent stent thrombosis dual antiplatelet therapy acetylsalicylic acid clopidogrel ( ADP-receptor antagonist ) routinely use ( 1 ) . Previous study report drug interaction clopidogrel several statin ( e.g . atorvastatin , simvastatin ) describe dose-dependent inhibition effect clopidogrel platelet aggregation . This drug interaction think due fact drug ( clopidogrel atorvastatin/simvastatin ) metabolize cytochrome P450 3A4 ( 2 , 3 ) . In contrast atorvastatin simvastatin , fluvastatin mainly metabolize cytochrome P450 2C9 . Metabolization clopidogrel mandatory effective platelet inhibition . Since patient coronary stent implantation treat clopidogrel 80 % patient coronary heart disease receive statin question whether drug-drug interaction great importance . In previous trial observe beneficial effect fluvastatin platelet inhibition top aspirin Clopidogrel ( 4 ) . There reduction platelet aggregation approximately 10 % , whereas atorvastatin pravastatin effect even slightly increase platelet aggregation . 2 . Aim The purpose present study 1 ) determine beneficial effect fluvastatin platelet aggregation comparison atorvastatin patient stable coronary artery 2 ) ass potential drug-drug interaction Clopidogrel atorvastatin . 3 . Patients Methods Approximately 100 patient include present study . All patient undergo coronary stent implantation drug elute stent . The first measurement platelet aggregation aspirin clopidogrel treatment ( load dose 600mg ) set 12 24 hour administration load dose clopidogrel . Any statin treatment stop 2 week ( washout phase statin treatment study inclusion ) PCI . After 2 week second platelet aggregation treatment ASA clopidogrel randomization fluvastatin 80mg atorvastatin 40mg per day addition dual antiplatelet therapy . Third measurement 1 month later crossover statin treatment another month . End study forth measurement platelet aggregation . Clinical follow-up ( MACE ) 2.5 , 6 12 month inclusion . Measured variable : 1 . Platelet aggregation assess follow method : · APACT-4 aggregometer ( Endothell , Switzerland , induce 5 , 20 µmol ADP 0.5mg/ml arachidonic acid ) ( 5 ) . 2 . Blood analysis : Blood smear , coagulation parameter , lipid profile , liver enzyme , creatinkinase , homocysteine , hs-CRP , BNP Sample size justification : It estimate 50 patient per treatment group provide 99 % power achieve 10 % difference platelet aggregation ( ± 10 standard deviation ) . 4 . Study Design Duration Duration : 12 month , 2.5 month assessment platelet aggregation Primary endpoint : platelet aggregation 2.5 month Secondary endpoint : MACE 12 month 5 . Inclusion Criteria - patient stent implantation follow treatment aspirin clopidogrel - routinely treat acetylsalicylic 100 mg/day 6 . Exclusion Criteria - acute coronary syndrome - use GPIIb/IIIa inhibitor - allergy acetylsalicylic acid , clopidogrel , statins - elevate liver enzyme ( &gt; 3 x norm value ) - muscle myopathy - active liver disease - recent gastrointestinal bleeding ( &lt; 3 month ) - know platelet dysfunction abnormal platelet count - pregnancy - indication treatment non-steroidal drug - indication long-term treatment drug metabolize cytochrome p450 3A4 2C9 7 . Literature 1 . Berger , P.B. , et al. , Clopidogrel versus ticlopidine intracoronary stent placement . J Am Coll Cardiol , 1999 . 34 ( 7 ) : p. 1891-4 . 2 . Lau , W. C. , L. A. Waskell , et al . ( 2003 ) . `` Atorvastatin reduce ability clopidogrel inhibit platelet aggregation : new drug-drug interaction . '' Circulation 107 ( 1 ) : 32-7 . 3 . Clarke TA , Waskell LA . The metabolism clopidogrel catalyze human cytochrome P450 3A inhibit atorvastatin . Drug Metab Dispos 2003 ; 31 ( 1 ) :53-9 4 . Wenaweser P. , et al . Do Statins Interfere With Antiaggregatory Effect Clopidogrel Patients With Stent Thrombosis ? Abstract presentation Swiss Cardiac Society , June 2005 , Lausanne 5 . McKenzie ME , Gurbel PA , Levine DJ , Serebruany VL . Clinical utility available method determine platelet function . Cardiology . 1999 ; 92 ( 4 ) :240-7. Review</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>patient stent implantation follow treatment aspirin clopidogrel routinely treat acetylsalicylic 100 mg/day acute coronary syndrome use GPIIb/IIIa inhibitor allergy acetylsalicylic acid , clopidogrel , statin elevate liver enzymes ( &gt; 3 x norm value ) muscle myopathy active liver disease recent gastrointestinal bleeding ( &lt; 3 month ) know platelet dysfunction abnormal platelet count pregnancy indication treatment nonsteroidal drug indication longterm treatment drug metabolize cytochrome p450 3A4 2C9</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>